SCHEMBL12256164

SCHEMBL12256164

O=C(O)c1ccccc1OC(=O)C(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 11/20 0.61
▸ HSD17B10 Q99714 7/20 0.61
▸ HPGD P15428 6/20 0.61
▸ ALDH1A1 P00352 9/20 0.59
▸ HMGB1 P09429 2/20 0.59
▸ NAPRT Q6XQN6 2/20 0.59
▸ ESR1 P03372 1/20 0.59
▸ ITGB3 P05106 1/20 0.59
▸ ITGA2B P08514 1/20 0.59
▸ TSHR P16473 1/20 0.59
▸ GGT1 P19440 1/20 0.59
▸ PTGS1 P23219 1/20 0.59
▸ PTGS2 P35354 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ MAPT P10636 2/20 0.58
▸ LMNA P02545 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ KMT2A Q03164 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9436992 0.83 KDM4E (0.62) KDM4EHSD17B10HPGDALDH1A1HMGB1
SCHEMBL7687512 0.81 KDM4E (0.61) KDM4EHSD17B10HPGDALDH1A1HMGB1
SCHEMBL12446771 0.81 KDM4E (0.61) KDM4EHSD17B10HPGDALDH1A1HMGB1
SCHEMBL1914531 0.81 KDM4E (0.66) KDM4EHSD17B10HPGDALDH1A1HMGB1
SCHEMBL14680714 0.81 KDM4E (0.61) KDM4EHSD17B10HPGDALDH1A1HMGB1
SCHEMBL15441430 0.80 KDM4E (0.64) KDM4EHSD17B10HPGDALDH1A1HMGB1
SCHEMBL28064330 0.80 KDM4E (0.59) KDM4EHSD17B10HPGDALDH1A1HMGB1
SCHEMBL12715457 0.80 KDM4E (0.64) KDM4EHSD17B10HPGDALDH1A1HMGB1
SCHEMBL9850317 0.79 KDM4E (0.62) KDM4EHSD17B10HPGDALDH1A1HMGB1
SCHEMBL19625924 0.79 KDM4E (0.62) KDM4EHSD17B10HPGDALDH1A1HMGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8709704-B2 Pattern forming method using developer containing organic solvent and rinsing solution for use in the pattern forming method FUJIFILM CORPORATION (JP) 2014-04-29 — — US disclosed
US-20120322007-A1 PATTERN FORMING METHOD, CHEMICAL AMPLIFICATION RESIST COMPOSITION AND RESIST FILM FUJIFILM CORPORATION (JP) 2012-12-20 — — US disclosed
US-20110229832-A1 PATTERN FORMING METHOD USING DEVELOPER CONTAINING ORGANIC SOLVENT AND RINSING SOLUTION FOR USE IN THE PATTERN FORMING METHOD FUJIFILM CORPORATION (JP) 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110229832-A1 PATTERN FORMING METHOD USING DEVELOPER CONTAINING ORGANIC SOLVENT AND RINSING SOLUTION FOR USE IN THE PATTERN FORMING METHOD RER1, RARA, RARG KDM4E 3329/4885HSD17B10 3814/4885HPGD 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback